Suppr超能文献

异态性毛细血管扩张共济失调症患者在接受异基因造血干细胞移植后完全淋巴造血重建,但仍出现致死性结局。

Fatal outcome despite full lympho-hematopoietic reconstitution after allogeneic stem cell transplantation in atypical ataxia telangiectasia.

机构信息

Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine Universität Düsseldorf, Medical Faculty, 40225, Düsseldorf, Germany.

出版信息

J Clin Immunol. 2012 Jun;32(3):438-40. doi: 10.1007/s10875-012-9654-7. Epub 2012 Feb 23.

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) has not been a therapeutic option in ataxia telangiectasia (AT) due to overwhelming toxicity of conditioning in the context of the global DNA repair deficiency. Furthermore HSCT is unable to cure neurological involvement of AT. We report on a Turkish child with a Hyper IgM phenotype disorder, in which clinical aspects of AT were absent and thus, AT not diagnosed. He was transplanted with a reduced toxicity, but full intensity conditioning regimen comprising treosulfan, fludarabine and ATG. The peritransplant period was uneventful and the patient was discharged at day +57. 8 months after HSCT, the patient developed hepatopathy with monoclonal gammopathy of unclear significance and died due to hepatic failure and encephalopathy at the age of 32 months. Post mortem high throughput sequencing revealed a mutation in the ATM gene.

摘要

由于全基因组 DNA 修复缺陷,异基因造血干细胞移植(HSCT)在共济失调毛细血管扩张症(AT)中并不是一种治疗选择。此外,HSCT 无法治愈 AT 的神经病变。我们报告了一名土耳其患有高免疫球蛋白 M 表型障碍的儿童,该儿童没有 AT 的临床特征,因此未被诊断为 AT。他接受了低强度、但完全强度的预处理方案,包括曲奥舒凡、氟达拉滨和 ATG。移植期间无并发症,患者在 HSCT 后第+57 天出院。8 个月后,患者出现肝毒性,伴有意义未明的单克隆丙种球蛋白血症,并因肝衰竭和脑病在 32 个月大时死亡。死后高通量测序显示 ATM 基因突变。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验